Lumida
/NHI
⌘K
National Health Investors Inc

National Health Investors Inc

NHI
$70.32USD+0.16%+0.11 today

MARKET CAP

3.5B

P/E (TTM)

22.7x

FWD P/E

DAY RANGE

$70 – $71

52W RANGE

$68
$91

AI Summary

Stalk
Sell NowMedium

NHI remains in a Stage 4 declining regime with price below all major EMAs and SMAs and the primary Support Failure pattern confirming bearish medium-term asymmetry. Short- and long-term trends are down, and rallies into the falling 9-EMA and 21-EMA have been consistently rejected. While the RSI is approaching oversold, there is no sign of a sustained reversal, so the optimal approach is to initiate short exposure now in the resistance area around the short-term EMAs.

  • SHOP to 40-50% portfolio, targeting 8-9% NOI growth H2
  • EPS guidance $4.74-$4.79 vs consensus $4.87, upside potential
  • Q2 FFO flat at $1.19/share; net income boosted by $22M sales
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$298.7M$278.2M$298.0M$311.5M$351.7M
YoY %-2.8%-6.9%+7.1%+4.5%+12.9%
P / Sales8.8x8.5x8.1x9.8x10.2x
EV / Sales13.1x12.8x12.1x13.7x13.7x
Gross Profit, Adj.$298.7M$278.2M$298.0M$311.5M$351.7M
YoY %-2.8%-6.9%+7.1%+4.5%+12.9%
Margin %100.0%100.0%100.0%100.0%100.0%
EV / Gross Profit13.1x12.8x12.1x13.7x13.7x
EBITDA, Adj.$268.0M$214.0M$268.8M$281.4M$313.0M
YoY %-5.2%-20.1%+25.6%+4.7%+11.2%
Margin %89.7%76.9%90.2%90.3%89.0%
EV / EBITDA14.6x16.7x13.4x15.1x15.4x
EBIT$186.2M$142.5M$196.3M$207.0M$227.6M
YoY %-6.1%-23.5%+37.8%+5.5%+9.9%
Margin %62.3%51.2%65.9%66.5%64.7%
EV / EBIT21.0x25.0x18.4x20.6x21.2x
Net Income$111.8M$66.4M$135.6M$137.9M$142.0M
YoY %-39.6%-40.6%+104.2%+1.7%+3.0%
Net Margin37.4%23.9%45.5%44.3%40.4%
EPS (GAAP)$2.44$1.48$3.13$3.13$3.02
YoY %-41.1%-39.3%+111.5%-3.5%